Skip to Content
Capgemini_Solutions_Data-driven-Research-and-Development
Solution

Data-driven R&D

Innovate at scale with the next generation of AI-powered R&D tools – designed with you, for you

Patient-centric healthcare – white paper4 MB pdf
Digital R&D in life sciences – brochure1,019 KB pdf

Turning data into value

The greatest medical discoveries of our day are coming from companies that use their data wisely. Most pharma and MedTech companies have rich data to draw from, but still struggle to extract optimal value. Just as inaccurate, insecure or disorganized data can impede an organization, the right data tools accelerate discoveries.

Specialized tools for skilled researchers

Designed by experts with experience across the life sciences sector, our Data-Driven R&D capabilities translate complexity into data you can use, and enable you to turn your insights into life-changing interventions.

We work with you to design hybrid-AI models that augment your key knowledge workers. It’s an approach that combines generative AI with traditional AI and scientific models to ensure safe and compliant outcomes aligned with your unique needs as researchers. Where generic solutions register c1ccccc1, our AI models see a benzene molecule, with all the relevant implications (toxicity, valence etc.).

We provide: 

  • Cloud-ready platform-as-a-code to industrialize data ingestion, build ML models, and deploy R&D AI applications at scale 
  • Enhanced industrialization of domain-driven data products and AI solutions with scalable platform or data mesh in a hybrid cloud environment
  • Improved insight generation and sharing across organization through our data & AI platforms.

Lots of solutions work with data. We design tools that work with life sciences researchers. From inception into production, our fully-integrated, scalable data and AI platforms provide a seamless workflow based 100% around your real-world needs.

    Integrating artificial intelligence (AI) into the drug discovery phase of pharmaceutical R&D

    Capgemini brings a blend of data science, IT and science capabilities to unravel the high complexity in pharmaceutical RD

    Read more

      Explore, engineer and generate insights

      A new cancer drug underperforms its comparator in 90% of participants. Have you hit a dead end, or are you on the road to developing a life-changing treatment via a secondary indication? The right AI tools can uncover trends that could be the difference between canceling a promising new medicine and bringing it to market.

      Experienced computational and life sciences experts from Capgemini work with your team to: 

      • accelerate and optimize your R&D value chain
      • improve analytics quality 
      • automate complex processes
      • improve probability of success

      Good AI is useful – it helps co-locate and classify information, saves time, and adds convenience.z

      Great AI makes multi-variate connections that even the most skilled people would likely have missed. It predicts the efficacy of drugs, and anticipates counter-indications, preventing harm to participants and trial results.

      Scale your data and hybrid-AI solutions across your organization

      The typical research and development flow of pharmaceuticals involves methodical, iterative experimentation across a range of scientific disciplines, including biology, chemistry, and materials. Hybrid-AI (including gen-AI) helps connect information and draw inferences, making it an incredible new tool. While many research teams have implemented generative AI solutions on a small scale, they are struggling to see immediate value and to scale their successes.

      Our data-driven R&D team will help you:

      • Identify complex scientific workflows that can be efficiently augmented with hybrid AI solutions
      • Define common architectures or building blocks across use cases to drive scale
      • Build out your critical data foundations and practices to feed these models useful information

      Our data-driven R&D team will ensure your data is Findable, Accessible, Interoperable and Reusable (FAIR); that it can be trusted, and that it can be leveraged in the drug discovery process to help bring your discoveries to market – quickly and safely.

      Contact one of our experts and find out how our data capabilities can further your R&D.

      Value-driven outcomes

        Next-gen clinical development

        Driving success and time-to-market in clinical drug development

        Read more

        Next-gen laboratories solutions

        To accelerate drug discovery, increase approval rates and reduce cycle times

        Read more

          Research and insights

          Capgemini Research Institute

          Data powered enterprises 2024
          Capgemini Research Institute

          Engineering biology
          Point of view

          Leading trustworthy AI in life sciences

          Expert perspectives

          Healthcare, Technology

          Managing life science innovation in a world of ever-increasing technological change

          Gerard Kerr
          Jan 20, 2023
          Data and AI

          The PULSAR principles of AI-ready data

          James Hinchliffe
          Sep 15, 2022
          Data and AI, Innovation, Intelligent industry, Technology, Trends

          The new generation of privacy preserving technologies

          Capgemini
          Jun 15, 2022

          Meet our experts

          James Hinchliffe

          Senior life sciences consultant, Capgemini Engineering Hybrid Intelligence
          James has been working with the R&D departments of global companies to release the potential locked away in their data since 2003. He provides clients with strategic advice on their priority IT programmes, consulting with them to develop realistic and achievable roadmaps to deliver real benefit from applying next-generation analytics methods to their data.

          Andrew Alderman

          Head of Industry (UK), Life Sciences
          Andrew focuses on the connection between life sciences R&D, technology, data and innovation. He has worked with clients from across the life science industry for over 22 years, supporting them on their path to becoming more data driven.

          Justin Melnick

          R&D Transformation Partner Life Sciences
          Justin leads Capgemini’s R&D for life sciences offer and is focused on the translatory role between the worlds of computational and biological sciences. He has 12 years experience in figuring out how to utilize technology to fundamentally impact human lives. A firm believer in tech-for-good and energized by the opportunity and ability to utilize technology in new ways that rewrite the business models of the life sciences world.

          Rayan Hashim

          R&D Transformation Partner Life Sciences